BR0312948A - Pramipexole em forma de dosagem uma vez ao dia - Google Patents
Pramipexole em forma de dosagem uma vez ao diaInfo
- Publication number
- BR0312948A BR0312948A BR0312948-9A BR0312948A BR0312948A BR 0312948 A BR0312948 A BR 0312948A BR 0312948 A BR0312948 A BR 0312948A BR 0312948 A BR0312948 A BR 0312948A
- Authority
- BR
- Brazil
- Prior art keywords
- pramipexole
- hours
- average
- composition
- absorption
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"PRAMIPEXOLE EM FORMA DE DOSAGEM UMA VEZ AO DIA". Uma composição farmacológica de administração oral inclui uma quantidade terapeuticamente efectiva de pramipexole ou um seu sal farmacologicamente aceitável e pelo menos excipiente farmacologicamente aceitável. Exibindo a referida composição pelo menos um de (a) um perfil de libertação in vitro em que em média não mais do que cerca de 20 % de pramipexole está dissolvido dentro de 2 horas depois de se colocar a composição em um teste de dissolução normalizado e (b) um perfil de absorção de pramipexole in vivo seguido a administração de dose única em humanos adultos saudáveis em que o tempo de alcançar uma média de 20 % de absorção é superior a cerca de 2 horas e/ou o tempo para alcançar uma média de 40 % de absorção é superior a cerca de 4 horas. A composição é útil para administração oral, não mais do que uma vez ao dia, a um sujeito tendo uma condição ou distúrbio para o qual é indicado um agonista do receptor dopamina.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39844702P | 2002-07-25 | 2002-07-25 | |
US39842702P | 2002-07-25 | 2002-07-25 | |
US47951403P | 2003-06-18 | 2003-06-18 | |
PCT/US2003/023522 WO2004010999A1 (en) | 2002-07-25 | 2003-07-25 | Pramipexole once-daily dosage form |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0312948A true BR0312948A (pt) | 2005-06-14 |
Family
ID=31192088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0312948-9A BR0312948A (pt) | 2002-07-25 | 2003-07-25 | Pramipexole em forma de dosagem uma vez ao dia |
Country Status (40)
Country | Link |
---|---|
US (2) | US8679533B2 (pt) |
EP (2) | EP1536792B1 (pt) |
JP (1) | JP4607584B2 (pt) |
KR (2) | KR101066374B1 (pt) |
CN (1) | CN1671381B (pt) |
AP (1) | AP2223A (pt) |
AR (1) | AR040682A1 (pt) |
AU (1) | AU2003256921B2 (pt) |
BR (1) | BR0312948A (pt) |
CA (1) | CA2493629C (pt) |
CU (1) | CU23468B7 (pt) |
CY (2) | CY1114263T1 (pt) |
DE (1) | DE20321906U1 (pt) |
DK (2) | DK2289514T5 (pt) |
EA (1) | EA017595B1 (pt) |
EC (1) | ECSP055569A (pt) |
ES (2) | ES2421787T3 (pt) |
GE (1) | GEP20074047B (pt) |
HK (1) | HK1078007A1 (pt) |
HR (1) | HRP20041234B1 (pt) |
IL (1) | IL166076A0 (pt) |
IS (1) | IS7613A (pt) |
MA (1) | MA27372A1 (pt) |
ME (1) | ME00347B (pt) |
MX (1) | MXPA05000980A (pt) |
MY (1) | MY142204A (pt) |
NO (1) | NO20050481L (pt) |
NZ (1) | NZ562681A (pt) |
OA (1) | OA12889A (pt) |
PA (1) | PA8578501A1 (pt) |
PE (1) | PE20040134A1 (pt) |
PL (1) | PL375444A1 (pt) |
PT (2) | PT1536792E (pt) |
RS (1) | RS52764B (pt) |
SG (1) | SG177011A1 (pt) |
SI (2) | SI2289514T1 (pt) |
TW (1) | TWI351955B (pt) |
UY (1) | UY27913A1 (pt) |
WO (1) | WO2004010999A1 (pt) |
ZA (1) | ZA200500015B (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
US7365086B2 (en) * | 2003-07-25 | 2008-04-29 | Synthon Ip Inc. | Pramipexole acid addition salts |
SG164375A1 (en) * | 2004-08-13 | 2010-09-29 | Boehringer Ingelheim Int | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
EA201001083A1 (ru) | 2004-08-13 | 2011-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Композиция таблетки пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение |
JP4965261B2 (ja) * | 2004-10-01 | 2012-07-04 | 日本臓器製薬株式会社 | 固形医薬製剤 |
WO2006046256A1 (en) * | 2004-10-27 | 2006-05-04 | Alembic Limited | Extended release formulation of pramipexole dihydrochloride |
WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
WO2007090882A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical extended release compositions comprising pramipexole |
US20090041844A1 (en) * | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
US8518926B2 (en) * | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
CN101448498B (zh) | 2006-05-16 | 2011-04-27 | 诺普神经科学股份有限公司 | R(+)和s(-)普拉克索的组合物以及使用该组合物的方法 |
US20080254118A1 (en) * | 2007-04-11 | 2008-10-16 | Hans-Werner Wernersbach | Process for preparing pramipexole dihydrochloride tablets |
US8524695B2 (en) * | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
EP2129382A4 (en) | 2007-02-21 | 2011-01-19 | Univ Michigan | COMPOSITIONS AND METHODS FOR TRANQUILIZATION OF THE CARDIAC MUSCLE |
US8519148B2 (en) | 2007-03-14 | 2013-08-27 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
CA2688074A1 (en) * | 2007-05-25 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation comprising pramipexole |
WO2008150741A1 (en) * | 2007-06-04 | 2008-12-11 | Drugtech Corporation | Controlled release dopamine agonist compositions |
EP2291178A4 (en) * | 2008-06-09 | 2013-07-24 | Supernus Pharmaceuticals Inc | PRAMIPEXOL FORMULATIONS WITH CONTROLLED RELEASE |
CN102186350A (zh) | 2008-08-19 | 2011-09-14 | 诺普神经科学股份有限公司 | 使用(r)-普拉克索的组合物与方法 |
AU2010234244A1 (en) * | 2009-04-09 | 2011-10-13 | Purdue Pharma | Once-daily oral IR/CR pramipexole formulation |
WO2011002891A1 (en) * | 2009-07-02 | 2011-01-06 | Supernus Pharmaceuticals, Inc. | A method of treatment of a neurological disorder |
WO2011037976A2 (en) * | 2009-09-22 | 2011-03-31 | Dr. Reddy's Laboratories Limited | Pramipexole pharmaceutical formulations |
WO2011086182A2 (en) * | 2010-01-18 | 2011-07-21 | Synthon Bv | Pramipexole extended release tablets |
TR201001862A1 (tr) * | 2010-03-11 | 2011-10-21 | Sanovel �La� San.Ve T�C.A.�. | Kontrollü salım gerçekleştiren pramipeksol formülasyonları. |
WO2011128914A2 (en) | 2010-04-15 | 2011-10-20 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of pramipexole |
EP2575780A1 (en) | 2010-05-24 | 2013-04-10 | Lupin Limited | Extended release formulation of pramipexole |
CN102670550A (zh) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | 盐酸普拉克索渗透泵型控释片 |
WO2013034173A1 (en) | 2011-09-06 | 2013-03-14 | Synthon Bv | Pramipexole extended release tablets |
CN102406626B (zh) * | 2011-12-02 | 2013-08-28 | 深圳海王药业有限公司 | 盐酸普拉克索缓释片剂及其制备方法 |
US9512096B2 (en) | 2011-12-22 | 2016-12-06 | Knopp Biosciences, LLP | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
EP2732812A1 (de) | 2012-11-15 | 2014-05-21 | Aristo Pharma GmbH | Pramipexol-Retardtablettenformulierung |
CN103058953B (zh) * | 2012-11-22 | 2015-03-25 | 刘炜 | 用于治疗神经疾病的四氢苯并噻唑衍生物 |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
EP3838271A1 (en) | 2013-07-12 | 2021-06-23 | Knopp Biosciences LLC | Treating elevated levels of eosinophils and/or basophils |
CA2921378A1 (en) | 2013-08-13 | 2015-02-19 | Knopp Biosciences Llc | Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders |
DK3033081T3 (da) | 2013-08-13 | 2021-05-31 | Knopp Biosciences Llc | Sammensætninger og fremgangsmåder til behandling af kronisk urticaria |
CN104606162B (zh) * | 2015-01-07 | 2017-03-29 | 海南康虹医药科技开发有限公司 | 一种盐酸普拉克索缓释制剂及其制备方法 |
CN104784155B (zh) * | 2015-05-15 | 2018-02-23 | 中国药科大学 | 一种盐酸普拉克索组合微丸胶囊及其制备方法 |
CN105030721B (zh) * | 2015-08-30 | 2018-05-04 | 南京康川济医药科技有限公司 | 一种含有盐酸普拉克索的口服固体组合物 |
EP3522843B1 (en) * | 2016-10-07 | 2022-09-21 | Transwell Biotech Co., Ltd. | Pramipexole transdermal delivery system and uses thereof |
WO2018115338A1 (de) * | 2016-12-21 | 2018-06-28 | Hso Herbert Schmidt Gmbh & Co. Kg | Beizlösung zum beizen von kunststoffen |
AU2018258117A1 (en) * | 2017-04-24 | 2019-12-12 | Chase Therapeutics Corporation | Compositions and method for treating depression |
US11234961B2 (en) | 2017-08-17 | 2022-02-01 | Zi-Qiang Gu | Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2887440A (en) * | 1957-08-12 | 1959-05-19 | Dow Chemical Co | Enteric coating |
US3065143A (en) * | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
NL128902C (pt) * | 1960-06-06 | |||
US3458622A (en) * | 1967-04-07 | 1969-07-29 | Squibb & Sons Inc | Controlled release tablet |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
JPS58403B2 (ja) * | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | L− アスコルビンサンセイザイノ セイゾウホウ |
US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
SE8003805L (sv) | 1980-05-21 | 1981-11-22 | Haessle Ab | En farmaceutisk beredning med forbettrade utlosningsegenskap |
SE8103843L (sv) * | 1981-06-18 | 1982-12-19 | Astra Laekemedel Ab | Farmaceutisk mixtur |
US4424235A (en) * | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
DE3572485D1 (en) * | 1984-12-22 | 1989-09-28 | Thomae Gmbh Dr K | Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs |
US4738851A (en) * | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US4666612A (en) * | 1986-03-17 | 1987-05-19 | Kerr-Mcgee Chemical Corporation | Method for recovering a wood preservative from waste sludges |
US4772473A (en) * | 1986-06-16 | 1988-09-20 | Norwich Eaton Pharmaceuticals, Inc. | Nitrofurantoin dosage form |
US4709712A (en) * | 1986-10-22 | 1987-12-01 | Dermatalogical Products Of Texas | Polycarboxylic acid polymer gels as protective agents |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US4789549A (en) * | 1987-03-09 | 1988-12-06 | Warner-Lambert Company | Sustained release dosage forms |
US4859470A (en) * | 1988-06-02 | 1989-08-22 | Alza Corporation | Dosage form for delivering diltiazem |
GB8828020D0 (en) * | 1988-12-01 | 1989-01-05 | Unilever Plc | Topical composition |
US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5273975A (en) * | 1989-06-09 | 1993-12-28 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
FR2653337B1 (fr) | 1989-10-23 | 1992-02-07 | Dow Corning Sa | Element a liberation prolongee et procede pour le fabriquer. |
IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
EP0447168A3 (en) | 1990-03-16 | 1993-01-07 | Yamanouchi Pharmaceutical Co. Ltd. | Long acting granular pharmaceutical composition |
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5656296A (en) * | 1992-04-29 | 1997-08-12 | Warner-Lambert Company | Dual control sustained release drug delivery systems and methods for preparing same |
US5661171A (en) * | 1992-07-02 | 1997-08-26 | Oramed, Inc. | Controlled release pilocarpine delivery system |
RU2121830C1 (ru) | 1992-09-18 | 1998-11-20 | Яманоути Фармасьютикал Ко., ЛТД | Гидрогелевый препарат с длительным высвобождением лекарства |
DE4241013A1 (de) * | 1992-12-05 | 1994-06-09 | Boehringer Ingelheim Kg | Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung |
US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
US5458887A (en) * | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5484608A (en) | 1994-03-28 | 1996-01-16 | Pharmavene, Inc. | Sustained-release drug delivery system |
DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
US5650420A (en) | 1994-12-15 | 1997-07-22 | Pharmacia & Upjohn Company | Pramipexole as a neuroprotective agent |
WO1997004752A1 (en) | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
DE69615704T2 (de) | 1995-12-27 | 2002-07-11 | Janssen Pharmaceutica N.V., Beerse | Bioadhesive feste arzneimittelform |
US5846971A (en) * | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
JPH1017497A (ja) | 1996-07-02 | 1998-01-20 | Takeda Chem Ind Ltd | 徐放性製剤およびその製造方法 |
GB9619074D0 (en) | 1996-09-12 | 1996-10-23 | Smithkline Beecham Plc | Composition |
AU729529B2 (en) * | 1997-06-06 | 2001-02-01 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
CA2270975C (en) | 1997-07-02 | 2003-04-01 | Euro-Celtique, S.A. | Stabilized sustained release tramadol formulations |
CA2211778A1 (en) | 1997-08-14 | 1999-02-14 | Francois Carriere | Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents |
US7153845B2 (en) * | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US6624200B2 (en) * | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US6248358B1 (en) * | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
DE69819748T2 (de) * | 1997-09-12 | 2004-09-30 | Columbia Laboratories (Bermuda) Ltd. | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen |
CA2304819C (en) | 1997-09-29 | 2008-04-08 | Inhale Therapeutic Systems, Inc. | Perforated microparticles and methods of use |
US6197339B1 (en) | 1997-09-30 | 2001-03-06 | Pharmacia & Upjohn Company | Sustained release tablet formulation to treat Parkinson's disease |
US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US20020013304A1 (en) | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
US20020054911A1 (en) * | 2000-05-11 | 2002-05-09 | Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi | Novel oral dosage form for carvedilol |
FR2772615B1 (fr) | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
GB9802201D0 (en) | 1998-02-03 | 1998-04-01 | Cerestar Holding Bv | Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules |
AU748396C (en) * | 1998-03-11 | 2003-01-23 | Smithkline Beecham Corporation | Composition |
EA004474B1 (ru) | 1998-05-15 | 2004-04-29 | Фармация Энд Апджон Компани | Комбинированное лечение заболевания цнс, особенно болезни паркинсона, путём совместного введения каберголина и прамипексола |
US6312728B1 (en) | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
TW407058B (en) * | 1998-07-17 | 2000-10-01 | Dev Center Biotechnology | Oral cisapride dosage forms with an extended duration |
US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US6270805B1 (en) | 1998-11-06 | 2001-08-07 | Andrx Pharmaceuticals, Inc. | Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
CA2371940C (en) * | 1999-03-31 | 2008-07-15 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
DE19927688A1 (de) | 1999-06-17 | 2000-12-21 | Gruenenthal Gmbh | Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
CA2416233A1 (en) * | 1999-07-13 | 2001-01-18 | Alpha Research Group, Llc | Compositions and methods for the treatment of parkinson's disease |
GB9923045D0 (en) | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
AU7620600A (en) | 1999-09-30 | 2001-04-30 | General Hospital Corporation, The | Use of pramipexole as a treatment for cocaine craving |
CA2387819A1 (en) | 1999-10-19 | 2001-04-26 | Nps Pharmaceuticals, Inc. | Sustained-release formulations for treating cns-mediated disorders |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
EP1239856A1 (en) * | 1999-12-22 | 2002-09-18 | Pharmacia Corporation | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
CA2332691C (en) * | 2000-01-27 | 2007-11-27 | The York Group, Inc. | Death care merchandising system |
JP2003522144A (ja) | 2000-02-08 | 2003-07-22 | ユーロ−セルティーク,エス.エイ. | オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物 |
PE20011074A1 (es) * | 2000-02-23 | 2001-10-04 | Upjohn Co | Uso de pramipexol en el tratamiento de trastornos de adiccion |
WO2001062236A2 (en) * | 2000-02-24 | 2001-08-30 | Pharmacia & Upjohn Company | New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
US6955821B2 (en) * | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
US6372252B1 (en) | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
US6277875B1 (en) | 2000-07-17 | 2001-08-21 | Andrew J. Holman | Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
CA2418915A1 (en) * | 2000-08-08 | 2002-02-14 | Teva Pharmaceutical Industries Ltd. | Stable pergolide mesylate and process for making same |
ES2187249B1 (es) | 2000-09-18 | 2004-09-16 | Synthon Bv | Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles. |
SE0004671D0 (sv) * | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
EP2238975B1 (en) | 2001-07-04 | 2012-12-05 | Sun Pharma Advanced Research Company Ltd | Gastric retention controlled drug delivery system |
FR2827872A1 (fr) | 2001-07-30 | 2003-01-31 | Roussy Inst Gustave | Vesicules membranaires de fluide biologique preleve in vivo, leur preparation et utilisation dans la stimulation d'une reponse immunitaire |
US20030032661A1 (en) * | 2001-08-02 | 2003-02-13 | Boehringer Ingelheim Pharma Kg | Pramipexole as an anticonvulsant |
GB0125088D0 (en) | 2001-10-18 | 2001-12-12 | Smithkline Beecham Cork Ltd | New use |
WO2003053402A1 (en) | 2001-12-20 | 2003-07-03 | Pharmacia Corporation | Zero-order sustained released dosage forms and method of making the same |
US20030224050A1 (en) | 2002-01-04 | 2003-12-04 | Charles Chiao | Drug delivery system for sustained delivery of glipizide |
EP1480618B1 (en) | 2002-03-04 | 2009-06-03 | Ipsen Pharma | Sustained release drug formulations containing a carrier peptide |
ES2733044T1 (es) | 2002-04-05 | 2019-11-27 | Mundipharma Pharmaceuticals S L | Composición farmacéutica que contiene oxicodona y naloxona |
EA007156B1 (ru) | 2002-04-15 | 2006-08-25 | Адамс Лэборетриз, Инк. | Замедленно высвобождающие лекарственные композиции гвайфенезина |
US20030215498A1 (en) * | 2002-05-17 | 2003-11-20 | Harland Ronald S. | Rapidly disintegrating comressed tablets comprising biologically active compounds |
NZ537142A (en) | 2002-06-10 | 2008-01-31 | Wyeth Corp | Novel formate salt of O-desmethyl-venlafaxine |
US20060153908A1 (en) | 2002-06-27 | 2006-07-13 | Brian Strong | Spherical pellet formulations |
EP1552832A1 (en) * | 2002-07-11 | 2005-07-13 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
US20050226926A1 (en) * | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
CA2488860A1 (en) | 2002-07-25 | 2004-02-05 | Pharmacia Corporation | Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former |
AR040680A1 (es) * | 2002-07-25 | 2005-04-13 | Pharmacia Corp | Composicion de tabletas de liberacion sostenida |
US20040121010A1 (en) * | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
CA2415154C (en) | 2002-12-24 | 2009-06-16 | Biovail Laboratories Inc. | Modified release formulations of selective serotonin re-uptake inhibitors |
WO2004058228A1 (en) | 2002-12-24 | 2004-07-15 | Lupin Limited | Enteric coated fluoxetine composition |
US20050020589A1 (en) * | 2003-06-18 | 2005-01-27 | Pfizer Inc. | Sustained-release tablet composition comprising a dopamine receptor agonist |
SG164375A1 (en) * | 2004-08-13 | 2010-09-29 | Boehringer Ingelheim Int | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
EA201001083A1 (ru) * | 2004-08-13 | 2011-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Композиция таблетки пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение |
WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
US20090041844A1 (en) * | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
EP1886665A1 (en) * | 2006-08-01 | 2008-02-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Gastro retentive delivery system |
CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
CN104721168A (zh) * | 2006-08-25 | 2015-06-24 | 贝林格尔·英格海姆国际有限公司 | 控制释放系统及其制造方法 |
-
2003
- 2003-07-24 PA PA20038578501A patent/PA8578501A1/es unknown
- 2003-07-24 MY MYPI20032783A patent/MY142204A/en unknown
- 2003-07-24 PE PE2003000736A patent/PE20040134A1/es not_active Application Discontinuation
- 2003-07-24 US US10/626,275 patent/US8679533B2/en active Active
- 2003-07-24 AR AR20030102667A patent/AR040682A1/es unknown
- 2003-07-25 WO PCT/US2003/023522 patent/WO2004010999A1/en active Application Filing
- 2003-07-25 ES ES10174089T patent/ES2421787T3/es not_active Expired - Lifetime
- 2003-07-25 SI SI200332276T patent/SI2289514T1/sl unknown
- 2003-07-25 MX MXPA05000980A patent/MXPA05000980A/es unknown
- 2003-07-25 DK DK10174089.2T patent/DK2289514T5/da active
- 2003-07-25 TW TW092120436A patent/TWI351955B/zh not_active IP Right Cessation
- 2003-07-25 CA CA2493629A patent/CA2493629C/en not_active Expired - Fee Related
- 2003-07-25 PL PL03375444A patent/PL375444A1/xx unknown
- 2003-07-25 GE GEAP8598A patent/GEP20074047B/en unknown
- 2003-07-25 PT PT37719598T patent/PT1536792E/pt unknown
- 2003-07-25 NZ NZ562681A patent/NZ562681A/en not_active IP Right Cessation
- 2003-07-25 AU AU2003256921A patent/AU2003256921B2/en not_active Expired
- 2003-07-25 RS RS115104A patent/RS52764B/en unknown
- 2003-07-25 PT PT101740892T patent/PT2289514E/pt unknown
- 2003-07-25 EP EP03771959.8A patent/EP1536792B1/en not_active Expired - Lifetime
- 2003-07-25 BR BR0312948-9A patent/BR0312948A/pt not_active IP Right Cessation
- 2003-07-25 JP JP2004524936A patent/JP4607584B2/ja not_active Expired - Fee Related
- 2003-07-25 DK DK03771959.8T patent/DK1536792T3/da active
- 2003-07-25 EA EA200500080A patent/EA017595B1/ru not_active IP Right Cessation
- 2003-07-25 CN CN038178311A patent/CN1671381B/zh not_active Expired - Fee Related
- 2003-07-25 AP AP2005003206A patent/AP2223A/xx active
- 2003-07-25 ME MEP-2008-522A patent/ME00347B/me unknown
- 2003-07-25 OA OA1200500017A patent/OA12889A/en unknown
- 2003-07-25 KR KR1020077012380A patent/KR101066374B1/ko not_active IP Right Cessation
- 2003-07-25 SI SI200332311T patent/SI1536792T1/sl unknown
- 2003-07-25 EP EP10174089.2A patent/EP2289514B9/en not_active Expired - Lifetime
- 2003-07-25 DE DE20321906U patent/DE20321906U1/de not_active Expired - Lifetime
- 2003-07-25 ES ES03771959.8T patent/ES2436745T3/es not_active Expired - Lifetime
- 2003-07-25 KR KR1020057001294A patent/KR20050025654A/ko not_active Application Discontinuation
- 2003-07-25 SG SG2008086357A patent/SG177011A1/en unknown
- 2003-07-31 UY UY27913A patent/UY27913A1/es not_active Application Discontinuation
-
2004
- 2004-12-23 IS IS7613A patent/IS7613A/is unknown
- 2004-12-30 IL IL16607604A patent/IL166076A0/xx unknown
- 2004-12-30 HR HRP20041234AA patent/HRP20041234B1/hr not_active IP Right Cessation
-
2005
- 2005-01-03 ZA ZA200500015A patent/ZA200500015B/en unknown
- 2005-01-24 EC EC2005005569A patent/ECSP055569A/es unknown
- 2005-01-25 CU CU20050019A patent/CU23468B7/es unknown
- 2005-01-25 MA MA28067A patent/MA27372A1/fr unknown
- 2005-01-27 NO NO20050481A patent/NO20050481L/no not_active Application Discontinuation
- 2005-11-09 HK HK05109990.6A patent/HK1078007A1/xx not_active IP Right Cessation
-
2013
- 2013-07-26 CY CY20131100643T patent/CY1114263T1/el unknown
- 2013-11-01 CY CY20131100969T patent/CY1114566T1/el unknown
-
2014
- 2014-01-28 US US14/165,743 patent/US20140141079A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0312948A (pt) | Pramipexole em forma de dosagem uma vez ao dia | |
JP6659072B2 (ja) | メラトニンアゴニスト治療 | |
Zupancic et al. | Agomelatine: a preliminary review of a new antidepressant | |
Huber et al. | Delusional parasitosis and the dopamine transporter. A new insight of etiology? | |
ES2170069T3 (es) | 1-alfa-hidroxiprevitamina d para administracion oral. | |
AR040709A1 (es) | Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion | |
NO20052019L (no) | Blanding for a inhibere sekresjon av magesyre | |
AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
KR100573352B1 (ko) | 알츠하이머 질환의 치료 방법 | |
Reginster et al. | A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis | |
Lever et al. | Nifedipine enhances the bronchodilator effect of salbutamol. | |
BR0008057A (pt) | Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada | |
LV11940B (en) | APPLICATION OF MELATONINE TO TREATMENT OF PERSONS RESPONSIBLE FOR MEDICINAL PRODUCTS \ t | |
PT1397128E (pt) | Agonista opiáceo kapa para o tratamento de doenças da bexiga irritável. | |
Zimmermann et al. | Prolonged inhibition of presynaptic catecholamine synthesis with α-methyl-para-tyrosine attenuates the circadian rhythm of human TSH secretion | |
CR7660A (es) | Forma de dosificacion de pramipexol en una dosis unica diaria | |
NO20024043L (no) | Nye galeniske former for oral administrasjon med forlenget frigjöring av molsidomin | |
BRPI0506710A (pt) | composições farmacêuticas de liberação controlada | |
Jalava et al. | Concentration of carprofen in the serum and the synovial fluid in rheumatoid arthritis patients | |
NO20032581L (no) | Farmasöytisk formulering av gepiron for oral administrering | |
Blake et al. | Oral tenoxicam for peripheral orthopaedic surgery: a pharmacokinetic study | |
TH87764B (th) | รูปแบบปริมาณยาที่รับประทานวันละ 1 ครั้งของพรามีเพคโซล | |
Alván et al. | Clinical effects of indomethacin and additive clinical effect of indomethacin during salicylate maintenance therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 31/428, 9/20, 9/28; A61P 25/16, 43/00 Ipc: A61K 31/428 (2011.01), A61K 9/20 (2011.01), A61K 9 |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |